2025 France Adenovirus Vaccine Market Revenue Opportunities Report
Description
The 2025 France Adenovirus Vaccine Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Adenovirus Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the adenovirus vaccine market in France are Sanofi, Johnson & Johnson (Janssen), AstraZeneca, and Ceva.
Sanofi is a global leader in vaccine production investing over €490 million in a state-of-the-art vaccine manufacturing and R&D facility at Neuville sur Saône and Marcy-l'Étoile. This positions France as a hub for innovative vaccine development, including adenovirus technology, with a workforce of about 7,200 in the Rhône-Alpes region supporting production and research. Johnson & Johnson's Janssen unit leverages its AdVac® adenovirus platform, approved by the European Commission for its Ebola vaccine, and is also developing COVID-19 and other viral vaccines using adenoviral vectors, reflecting its commitment to adenovirus-based vaccines in the region.
AstraZeneca manufactures the widely used ChAdOx1-S adenovirus-based COVID-19 vaccine (Vaxzevria), authorized in Europe, including France. AstraZeneca focuses on large-scale vaccine production and pandemic preparedness using adenoviral vector technology. Ceva, with operations in France through Cevac Biovac, specializes in veterinary vaccines, including adenovirus-based platforms for poultry diseases, contributing to the adenovirus vaccine market in the animal health segment. These companies collectively advance adenovirus vaccine innovation, leveraging France's manufacturing and R&D infrastructure.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Adenovirus Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the adenovirus vaccine market in France are Sanofi, Johnson & Johnson (Janssen), AstraZeneca, and Ceva.
Sanofi is a global leader in vaccine production investing over €490 million in a state-of-the-art vaccine manufacturing and R&D facility at Neuville sur Saône and Marcy-l'Étoile. This positions France as a hub for innovative vaccine development, including adenovirus technology, with a workforce of about 7,200 in the Rhône-Alpes region supporting production and research. Johnson & Johnson's Janssen unit leverages its AdVac® adenovirus platform, approved by the European Commission for its Ebola vaccine, and is also developing COVID-19 and other viral vaccines using adenoviral vectors, reflecting its commitment to adenovirus-based vaccines in the region.
AstraZeneca manufactures the widely used ChAdOx1-S adenovirus-based COVID-19 vaccine (Vaxzevria), authorized in Europe, including France. AstraZeneca focuses on large-scale vaccine production and pandemic preparedness using adenoviral vector technology. Ceva, with operations in France through Cevac Biovac, specializes in veterinary vaccines, including adenovirus-based platforms for poultry diseases, contributing to the adenovirus vaccine market in the animal health segment. These companies collectively advance adenovirus vaccine innovation, leveraging France's manufacturing and R&D infrastructure.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
